NAcM-OPT

• Description:

  NAcM-OPT is an orally bioavailable cullin neddylation 1 (DCN1) inhibitor, which potently inhibits the DCN1-UBE2M interaction[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  E1/E2/E3 Enzyme; NEDD8-activating Enzyme

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/NAcM-OPT.html

• Purity:

  99.65

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(NC1=CC=C(Cl)C(Cl)=C1)N(C2CCN(CCCC)CC2)CC3=CC=CC=C3

• Molecular Formula:

  C23H29Cl2N3O

• Molecular Weight:

  434.40

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Hammill JT, et al. Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1) -Mediated Cullin Neddylation. J Med Chem. 2018 Apr 12;61 (7) :2694-2706.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2089293-61-6]